{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:02:04Z","timestamp":1791061324651,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK56338"],"award-info":[{"award-number":["DK56338"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10620-023-07886-5","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T09:03:03Z","timestamp":1677661383000},"page":"1691-1697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6908-8317","authenticated-orcid":false,"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"7886_CR1","unstructured":"FDA. Vonoprazan Package Insert, 2022. Available at: http:\/\/www.phathompharma.com\/wp-content\/uploads\/VOQUEZNA-TRIPLE-PAK-and-VOQUEZNA-DUAL-PAK-FDA-Final-Label-3.pdf#page=38. Accessed 6\/10\/2022, 2022."},{"key":"7886_CR2","doi-asserted-by":"crossref","unstructured":"Chey WD, M\u00e9graud F, Laine L, L\u00f3pez LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: Randomized Clinical Trial Gastroenterology. 2022.","DOI":"10.1053\/j.gastro.2022.05.055"},{"key":"7886_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.03.026","volume":"20","author":"DY Graham","year":"2022","unstructured":"Graham DY, Liou JM. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship. Clin Gastroenterol Hepatol. 2022;20:e971.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7886_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1146\/annurev-med-042220-020814","volume":"73","author":"YC Lee","year":"2022","unstructured":"Lee YC, Dore MP, Graham DY. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022;73:183\u2013195.","journal-title":"Annu Rev Med."},{"key":"7886_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12941-018-0281-x","volume":"17","author":"H Tanabe","year":"2018","unstructured":"Tanabe H, Yoshino K, Ando K et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018;17:29.","journal-title":"Ann Clin Microbiol Antimicrob."},{"key":"7886_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","volume":"59","author":"S Kiyotoki","year":"2020","unstructured":"Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of Vonoprazan for Helicobacter pylori Eradication. Internal Medicine. 2020;59:153\u2013161.","journal-title":"Internal Medicine."},{"key":"7886_CR7","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439\u20131446.","journal-title":"Gut."},{"key":"7886_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10620-018-5288-9","volume":"64","author":"DY Graham","year":"2019","unstructured":"Graham DY, Optimal PPI. Dosing for Improving GERD Symptoms: Is Timing Everything? Dig. Dis Sci. 2019;64:4\u20136.","journal-title":"Dig. Dis Sci."},{"key":"7886_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/cpdd.1009","volume":"11","author":"DJ Mulford","year":"2022","unstructured":"Mulford DJ, Leifke E, Hibberd M, Howden CW. The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan. Clin Pharmacol Drug Dev. 2022;11:278\u2013284.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"7886_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/jcph.2019","volume":"62","author":"C Scarpignato","year":"2022","unstructured":"Scarpignato C, Leifke E, Smith N et al. A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race Disease Status, and Other Covariates on Exposure. J Clin Pharmacol. 2022;62:801\u2013811.","journal-title":"J Clin Pharmacol."},{"key":"7886_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/jps.2600790512","volume":"79","author":"DY Graham","year":"1990","unstructured":"Graham DY, Smith JL, Bouvet AA. What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations. J. Pharm. Sci. 1990;79:420\u2013424.","journal-title":"J. Pharm. Sci."},{"key":"7886_CR12","unstructured":"HERTZ AF. THE MOTOR FUNCTIONS OF THE STOMACH QJM: An International Journal of Medicine. 1910;os3:373\u2013394."},{"key":"7886_CR13","first-page":"66","volume":"31","author":"K Kihira","year":"1996","unstructured":"Kihira K, Satoh K, Saifuku K et al. Endoscopic topical therapy for the treatment of Helicobacter pylori infection. J. Gastroenterol. 1996;31:66\u201368.","journal-title":"J. Gastroenterol."},{"key":"7886_CR14","doi-asserted-by":"publisher","first-page":"175628482110640","DOI":"10.1177\/17562848211064080","volume":"14","author":"A Shiotani","year":"2021","unstructured":"Shiotani A, Roy P, Lu H, Graham DY. Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therap Adv Gastroenterol. 2021;14:17562848211064080.","journal-title":"Therap Adv Gastroenterol."},{"key":"7886_CR15","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/S0016-5085(97)80026-1","volume":"113","author":"RJ Hopkins","year":"1997","unstructured":"Hopkins RJ. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Gastroenterology. 1997;113:S126\u2013S130.","journal-title":"Gastroenterology."},{"key":"7886_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.14309\/ajg.0000000000001659","volume":"117","author":"DY Graham","year":"2022","unstructured":"Graham DY, Moss SF. Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When. How, Why Am J Gastroenterol. 2022;117:524\u2013528.","journal-title":"How, Why Am J Gastroenterol."},{"key":"7886_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/gutjnl-2016-311796","volume":"66","author":"DY Graham","year":"2017","unstructured":"Graham DY. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues.Gut. 2017;66:384\u2013386.","journal-title":"Gut."},{"key":"7886_CR18","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.cgh.2017.09.033","volume":"6","author":"DY Graham","year":"2018","unstructured":"Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;6:800\u2013808.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"#cr-split#-7886_CR19.1","doi-asserted-by":"crossref","unstructured":"Li M, Oshima T, Horikawa Tet al. . Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori Helicobacter. 2018;23:e12495","DOI":"10.1111\/hel.12495"},{"key":"#cr-split#-7886_CR19.2","doi-asserted-by":"crossref","unstructured":"Sue S, Ogushi M, Arima Iet al. . Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial Helicobacter. 2018;23:e12456.","DOI":"10.1111\/hel.12456"},{"key":"#cr-split#-7886_CR20.1","doi-asserted-by":"crossref","unstructured":"Jenkins H, Sakurai Y, Nishimura Aet al. . Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects Aliment. Pharmacol. Ther. 2015;41:636-648","DOI":"10.1111\/apt.13121"},{"key":"#cr-split#-7886_CR20.2","doi-asserted-by":"crossref","unstructured":"Sakurai Y, Nishimura A, Kennedy Get al. . Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese\/non-Japanese subjects Clin Transl. Gastroenterol. 2015;6:e94.","DOI":"10.1038\/ctg.2015.18"},{"key":"7886_CR21","doi-asserted-by":"crossref","unstructured":"Gunaratne AW, Hamblin H, Clancy Aet al. . Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections\u2014Exploratory study Helicobacter. 2021;26:e12830.","DOI":"10.1111\/hel.12830"},{"key":"7886_CR22","doi-asserted-by":"crossref","unstructured":"Suzuki T, Kagami T, Uotani Tet al. . Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin European Journal of Clinical Pharmacology. 2018;74:45\u201352;","DOI":"10.1007\/s00228-017-2324-1"},{"key":"7886_CR23","doi-asserted-by":"crossref","unstructured":"Sugimoto M, Furuta T, Shirai Net al. . Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes Clinical Pharmacology & Therapeutics. 2005;77:302\u2013311.","DOI":"10.1016\/j.clpt.2004.10.010"},{"key":"7886_CR24","first-page":"138","volume":"6","author":"M Sugimoto","year":"2009","unstructured":"Sugimoto M, Graham DY. High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication Nat. Clin. Pract. Gastroenterol. Hepatol. 2009;6:138\u2013139.","journal-title":"Clin. Pract. Gastroenterol. Hepatol."},{"key":"7886_CR25","doi-asserted-by":"crossref","unstructured":"Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: Effect of resistance, duration, and CYP2C19 genotype Helicobacter. 2015;21:85\u201390.","DOI":"10.1111\/hel.12287"},{"key":"7886_CR26","first-page":"1019","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan Gut. 2020;69:1019\u20131026.","journal-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan Gut."},{"key":"7886_CR27","first-page":"1159","volume":"36","author":"DY Graham","year":"2021","unstructured":"Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance J Gastroenterol Hepatol. 2021;36:1159\u20131163.","journal-title":"Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance J Gastroenterol Hepatol."},{"key":"7886_CR28","first-page":"4","volume":"2019","author":"Blaser MJ Missing microbes: how the overuse of antibiotics is fueling our modern plagues. New York: Macmillan; 2014;. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. W. H. O, City; World Health Organization;","year":"2017","unstructured":"Blaser MJ Missing microbes: how the overuse of antibiotics is fueling our modern plagues. New York: Macmillan; 2014;. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. W. H. O, City; World Health Organization; Tacconelli E, Pezzani MD. Public health burden of antimicrobial resistance in Europe The Lancet Infectious Diseases. 2017;2019:4\u20136.","journal-title":"Public health burden of antimicrobial resistance in Europe The Lancet Infectious Diseases."},{"key":"7886_CR29","unstructured":"Selection WECot, Medicines UoE, Organization WH The Selection and Use of Essential Medicines: Report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children). City: World Health Organization; 2014."},{"key":"7886_CR30","unstructured":"The 2019 WHO AWaRe classification of antibiotics for evaluation and monitoring of use. World Health Organization; 2019. (WHO\/EMP\/IAU\/2019.11)"},{"key":"7886_CR31","doi-asserted-by":"crossref","unstructured":"Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat. Rev. Gastroenterol Hepatol. 2017;7:383\u2013384","DOI":"10.1038\/nrgastro.2017.57"},{"key":"7886_CR32","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/jgh.15917","volume":"37","author":"Y Ouyang","year":"2022","unstructured":"Ouyang Y, Wang M, Xu Y-L, Zhu Y, Lu N-H, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2022;37:1666\u20131672.","journal-title":"Journal of Gastroenterology and Hepatology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-07886-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-07886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T04:22:04Z","timestamp":1682482924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-07886-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7886"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-07886-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"29 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel <i>H. pylori<\/i> therapies and has received research support for culture of <i>Helicobacter pylori<\/i>. He is also a consultant with Janssen Research & Development regarding potential gastrointestinal effects of drugs under development and has collaborated on research projects with American Molecular regarding molecular diagnostics for <i>H. pylori<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}